The purpose of this study is to determine whether ctDNA could help to evaluate whether to use drug adjuvant therapy after SBRT in patients with early lung cancer.
Patients pathologically diagnosed as non-small cell lung cancer, and was early stage（AJCC 8th）;
Patients aged between 18 -80 years; with expected survival time>3 months.
blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;
Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.) or intravenous medication;
Patients with any other severe and/or uncontrolled disease;
Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;
Parallel
drug adjuvant therapy
DrugThe adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
PFS
progression-free survival
PFS
progression-free survival
OS
overall survival
OS
overall survival
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
